# Bicara Therapeutics (BCAX) — Earnings

BCAX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bcax/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.82 |
| EPS estimate | −$0.82 |
| EPS surprise | −0.02% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 11, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/2023658/000162828026055765/bcax-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/d6e2e221-057e-005c-5e69-feaac6053632.html) |

Bicara Therapeutics reported Q2 2026 results on August 11, 2026. It posted a loss of $0.82 per share, in line with the $0.82 estimate; the source records a 0.02% miss. No revenue was reported and no revenue estimate was given. A year earlier, in Q2 2025, the loss was $0.50 per share, so the loss widened by about 64%.

The record is short, with eight quarters from Q3 2024, and every one of them is a loss. Losses have grown since early 2025. The loss for the full 2025 fiscal year was $2.53 per share, and the first half of 2026 adds up to a $1.75 loss, against $1.18 in the first half of 2025. The widest quarterly loss in the table is Q3 2024, at $1.60 per share, and the narrowest is Q4 2024, at $0.39. Bicara has beaten the EPS estimate once in eight quarters, in Q2 2025, by 9.75%. The largest misses were Q3 2024 and Q1 2025.

Bicara reported Q3 on November 12, 2024 and November 10, 2025. That points to around mid-November 2026 for the Q3 2026 report. It will show whether the quarterly loss stays in the range of the last few quarters.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 11, 2026 | −$0.82 | −$0.82 | -0.02% | — | — |
| Q1 2026 | May 11, 2026 | −$0.65 | −$0.93 | -43.23% | — | — |
| Q4 2025 | Mar 30, 2026 | −$0.67 | −$0.68 | -1.16% | — | — |
| Q3 2025 | Nov 10, 2025 | −$0.54 | −$0.67 | -23.82% | — | — |
| Q2 2025 | Aug 12, 2025 | −$0.55 | −$0.50 | 9.75% | — | — |
| Q1 2025 | May 13, 2025 | −$0.42 | −$0.68 | -63.86% | — | — |
| Q4 2024 | Mar 27, 2025 | −$0.33 | −$0.39 | -18.47% | — | — |
| Q3 2024 | Nov 12, 2024 | −$0.41 | −$1.60 | -290.24% | — | — |

## Frequently Asked Questions

### When did Bicara Therapeutics (BCAX) last report earnings?

Bicara Therapeutics last reported on Aug 11, 2026, covering fiscal Q2 2026.

### Did BCAX beat earnings estimates?

No. Bicara Therapeutics reported EPS of −$0.82 for Q2 2026 against a −$0.82 estimate — a 0.02% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).